Plural Eyes Trial |top| Jun 2026

Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are leading causes of vision loss worldwide. While current treatments, including anti-VEGF injections, have revolutionized patient outcomes, there remains a subset of patients who do not respond optimally or who experience a decline in efficacy over time. The PluralEyes trial was designed to address these gaps by investigating innovative therapeutic approaches and diagnostic tools that can better predict and improve treatment responses.